Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) 81.8% LOWER; received a Complete Response Letter from the FDA for its New Drug Application (NDA) for Silenor for the treatment of insomnia. Based on its review, the FDA has determined that the NDA cannot be approved in its present form.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) 78.6% LOWER; said based on an analysis by an independent Data Monitoring Committee, it has suspended the SYMMETRYSM trial, the Phase 3 clinical study comparing elesclomol in combination with paclitaxel to paclitaxel alone in chemo-naïve patients with stage IV metastatic melanoma. The decision to suspend the SYMMETRY trial